<p>Chuck Ryan from MSKCC joins to talk about various aspects of AR inhibition in prostate cancer and relative benefits and risks.</p>

Chuck Ryan from MSKCC joins to talk about various aspects of AR inhibition in prostate cancer and relative benefits and risks.

Episode 367: Abiraterone vs AR inhibitors (Fanta vs Coke) in Prostate Cancer

Broadcasting the latest developments in GU cancer

Hosted by Brian Rini and Tom Powles 

Brian Rini MD is a Professor of Cancer Research and Professor of Medicine (Hematology/Oncology), Vanderbilt-Ingram Cancer Center
Tom Powles is the Director of Barts Cancer Centre, St Bartholomew's Hospital and Professor of Genitourinary Oncology, Queen Mary University of London

Medicine

Health & Fitness

Broadcasting the latest developments in GU cancer Hosted by Brian Rini and Tom Powles Brian Rini MD is a Professor of Cancer Research and Professor of Medicine (Hematology/Oncology), Vanderbilt-Ingram Cancer Center Tom Powles is the Director of Barts Cancer Centre, St Bartholomew's Hospital and Professor of Genitourinary Oncology, Queen Mary University of London

Share Episode 367: Abiraterone vs AR inhibitors (Fanta vs Coke) in Prostate Cancer

Sign up to save your podcasts

Episode 367: Abiraterone vs AR inhibitors (Fanta vs Coke) in Prostate Cancer

Episode 367: Abiraterone vs AR inhibitors (Fanta vs Coke) in Prostate Cancer

More shows like The Uromigos

JAMA Editors' Summary

Prostate Cancer Update

NEJM This Week

JAMA Clinical Reviews

AFP: American Family Physician Podcast

ASCO Daily News

White Coat Investor Podcast

The Curbsiders Internal Medicine Podcast

The Peter Attia Drive

Annals On Call Podcast

The Clinical Problem Solvers

GU Cast | Urology Podcast

BioCentury This Week

Two Onc Docs

The View on GU | with Lalani and Wallis